FY2024 · ended Dec 31, 2024 · Revenue $210,000, -20.2% YoY · Filed Mar 31, 2026
Nexentis Technologies Inc. (NXTS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.8 million. As of Jun 30, 2026 it held $8.9 million in cash and investments and $219,000 in total debt.
Revenue (TTM)
$209,000
+19.9% vs year-ago TTM
Net income (TTM)
$-6.65M
-19.7% vs year-ago TTM
Operating cash flow (TTM)
$-4.43M
-62.8% vs year-ago TTM
Free cash flow
$-3.82M
+25.8% vs prior year
EPS (TTM)
$2.93
+283.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
5.11M
-71.3% vs prior year
Net cash
$8.66M
as of Jun 30, 2026
Operating margin
-2391.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NXTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1789192
- Former names
- N2OFF, Inc. (until Feb 25, 2026); Save Foods, Inc. (until Mar 19, 2024); Save Foods Inc. (until Apr 10, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $210,000 | $263,000 | $394,004 | $438,141 |
| Operating income | -$4.2M | -$3.3M | -$7.6M | -$5.8M | -$4.7M |
| Net income | -$4.0M | -$5.2M | -$6.5M | -$5.7M | -$4.8M |
| Diluted EPS | -$8.61 | -$27.74 | -$5.43 | — | — |
| Operating cash flow | -$3.8M | -$3.4M | -$3.2M | -$5.1M | -$4.1M |
| Free cash flow | -$3.8M | — | — | -$5.1M | -$4.2M |
| Total assets | $20.4M | $5.5M | $7.2M | $6.5M | $7.6M |
| Total liabilities | $4.7M | $892,000 | $786,000 | $754,872 | $1.2M |
| Stockholders' equity | $16.0M | $4.7M | $6.5M | $5.8M | $6.5M |
| Cash and investments | $4.1M | $2.2M | $4.4M | $5.7M | $6.8M |
| Total debt | $755,000 | $7,000 | $48,000 | $106,334 | $146,814 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 6, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 3, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Auditor change
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 22, 2026 | Jun 22, 2026 |
All 309 Nexentis Technologies Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.